Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Holdings Increased by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA raised its position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 104.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 355,961 shares of the company’s stock after buying an additional 181,831 shares during the quarter. Baldwin Wealth Partners LLC MA owned about 1.84% of Nuvectis Pharma worth $1,926,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of NVCT. GSA Capital Partners LLP raised its position in shares of Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after acquiring an additional 1,790 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Nuvectis Pharma in the 2nd quarter worth about $58,000. Nations Financial Group Inc. IA ADV acquired a new position in shares of Nuvectis Pharma in the 3rd quarter valued at about $63,000. Renaissance Technologies LLC grew its position in shares of Nuvectis Pharma by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after buying an additional 12,800 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Nuvectis Pharma by 49.8% during the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after acquiring an additional 26,489 shares during the period. Institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Stock Down 1.4 %

Shares of NASDAQ NVCT opened at $6.46 on Monday. The stock has a market capitalization of $124.81 million, a P/E ratio of -5.57 and a beta of 0.17. The firm’s 50-day moving average price is $5.26 and its two-hundred day moving average price is $6.34. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same period last year, the business posted ($0.37) EPS. As a group, equities research analysts expect that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Insider Transactions at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 17,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average cost of $4.70 per share, with a total value of $79,900.00. Following the acquisition, the insider now directly owns 2,612,000 shares of the company’s stock, valued at $12,276,400. This represents a 0.66 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ron Bentsur bought 20,000 shares of the business’s stock in a transaction on Friday, November 15th. The shares were acquired at an average cost of $4.92 per share, for a total transaction of $98,400.00. Following the purchase, the chief executive officer now directly owns 3,266,424 shares in the company, valued at $16,070,806.08. This represents a 0.62 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 43,500 shares of company stock worth $209,205. Insiders own 35.78% of the company’s stock.

Nuvectis Pharma Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.